Loss of CADM1/TSLC1 Expression and Its Clinicopathologic and Prognostic Significance in Colorectal Adenocarcinomas.
Young Jin Jun, Se Min Jang, Hulin Han, Hyun Jeong Kim, Kang Hong Lee, Ki-Seok Jang, Seung Sam Paik. College of Medicine, Hanyang University, Seoul, Republic of Korea
Background: Cell adhesion molecule 1 or tumor suppressor in lung carcinoma 1 (CADM1/TSLC1) is a novel tumor suppressor involving in cell adhesion, proliferation and apoptosis. CADM1/TSLC1 is expressed universally in human tissues and is frequently inactivated in a variety of human carcinomas. However, alterations of expression and clinicopathologic significance in colorectal adenocarcinomas have not been elucidated yet. The aim of this study was to investigate the CADM1/TSLC1 expression and its correlation with various clinicopathological parameters, as well as its effect on patient survival in colorectal adenocarcinomas.
Design: We examined the CADM1/TSLC1 expression in tissue microarrays of 513 colorectal adenocarcinomas by immunohistochemistry. The correlation between CADM1/TSLC1 expression and clinicopathologic characteristics, as well as prognosis, was investigated.
Results: CADM1/TSLC1 was expressed in the cytoplasm of tumor cells. 210 (41%) of 513 colorectal adenocarcinomas showed high CADM1/TSLC1 expression. 185 cases (36%) revealed downregulation of CADM1/TSLC1 expression and 118 cases (23%) showed loss of CADM1/TSLC1 expression. Loss of CADM1/TSLC1 expression was correlated with larger tumor size (p < 0.001), mucinous tumor type (p < 0.001), lymph node metastasis (p = 0.020), higher Dukes stage (p = 0.038), and poorer differentiation (p < 0.001). In univariate survival analysis, patients with loss of CADM1/TSLC1 expression revealed poorer overall survival and disease-free survival (p = 0.041 and p = 0.036, respectively, log-rank test). In multivariate survival analysis with the Cox proportional hazards model, CADM1/TSLC1 expression was not an independent prognostic factor of overall survival and disease-free survival (p = 0.074 and p = 0.087, respectively).
Conclusions: Our results demonstrated that loss or downregulation of CADM1/TSLC1 expression is a relatively frequent event in the development of colorectal adenocarcinomas. We conclude that loss of CADM1/TSLC1 expression may play an important role in cancer progression and aggressive phenotype of colorectal adenocarcinomas and can be a target biomarker for molecular staging or therapeutic approach of patients with colorectal adenocarcinomas.
Wednesday, March 2, 2011 9:30 AM
Poster Session V # 53, Wednesday Morning